Want to see IN:HIKAL full AI Analyst Report?
HIKAL Stock Chart & Stats
₹227.05
-₹7.35(-1.92%)
At close: 4:00 PM EST
₹227.05
-₹7.35(-1.92%)
Day’s Range― - ―
52-Week Range₹145.95 - ₹354.75
Previous CloseN/A
Volume141.84K
Average Volume (3M)34.88K
Market Cap
₹28.23B
Enterprise Value₹34.81K
Total Cash (Recent Filing)₹138.00M
Total Debt (Recent Filing)₹6.84B
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)-3.96
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.51
Price to Sales (P/S)1.06
P/FCF Ratio20.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.1
Revenue Forecast (FY)₹19.62B
Bulls Say, Bears Say
Bulls Say
Cash GenerationDespite a loss-making year, the company converted operations into positive operating and free cash flow in 2026. This durable cash generation supports working capital, debt servicing and selective reinvestment, providing financial resilience over the next several months even if earnings remain uneven.
Manageable LeverageMaterial debt reduction and debt around 25% of assets indicate a manageable leverage profile and improved balance-sheet flexibility. With a sizable equity base, the company has lower near-term refinancing risk and room to fund capex or strategy shifts without immediate pressure from creditors.
CDMO & Diversified End MarketsA hybrid model of CDMO services plus manufactured actives across pharma and agro gives diversified, recurring revenue potential and structural demand from outsourcing. End-market breadth and capabilities in scale-up/tech transfer provide durable competitive positioning for multi-year contract wins.
Bears Say
Profitability DeteriorationThe swing to a net loss despite positive gross profit points to margin compression and elevated operating costs. Continued negative earnings would erode retained earnings, limit reinvestment, and could reverse recent leverage improvements if profitability is not restored within several quarters.
Weak Revenue TrendNegative and inconsistent top-line growth reduces visibility into future utilization and scale benefits. For a manufacturing/CDMO player, weaker volumes impair fixed-cost absorption, pressure margins and make multi-period planning for capacity and pricing more challenging across client contracts.
Volatile Free Cash FlowWhile 2026 showed positive free cash flow, the multi-year volatility and prior negative FCF signal swings in capex, working capital or project timing. This unpredictability complicates funding of growth projects, dividends or buybacks and raises sensitivity to further earnings downdrafts.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹145.95 and its highest was ₹354.75 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹28.23B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on May 27, 2026. The company reported ₹4 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.2 which represents an annual dividend yield of 0.44%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of ₹4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.217%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―
Unichem Laboratories Limited
―